Vitamin K2 MK-7

Vitamin K2 MK-7 is the all-trans form of menaquinone-7 that activates gamma-carboxylation of osteocalcin and matrix GLA protein (MGP), directing calcium into bone matrix while inhibiting arterial calcification. Its exceptionally long plasma half-life of 48–92 hours—roughly 10-fold greater than vitamin K1—enables sustained extrahepatic tissue carboxylation at supplemental doses of 100–200 mcg daily, with RCT evidence supporting measurable improvements in bone mineral density and vascular elasticity.

Origin & History

Menaquinone-7 is produced naturally through the fermentation of soybeans by Bacillus subtilis natto, a process originating in Japan where the resulting food product—natto—has been consumed for over a millennium. Natto remains the richest known dietary source of MK-7, with concentrations far exceeding any other food. Commercial MK-7 supplements are derived from optimized Bacillus subtilis fermentation processes, with industrial conditions calibrated at approximately pH 6.58, 35°C, and 200 rpm agitation to maximize trans-isomer yield and purity.

Historical & Cultural Context

Natto, the fermented soybean food produced by Bacillus subtilis natto fermentation, has been consumed in Japan for over 1,000 years, with documented references to its preparation dating to the Heian period (794–1185 CE), where it was noted for purported benefits to blood circulation, bowel regularity, and metabolic vitality. Traditional Japanese medicine attributed regular natto consumption to cardiovascular and skeletal longevity, consistent with epidemiological observations that regions of Japan with highest natto consumption correlate with lower hip fracture rates and lower incidence of certain cardiovascular pathologies. The isolation and characterization of MK-7 as the primary bioactive component of natto responsible for its extrahepatic vitamin K activity was not accomplished until modern analytical chemistry and nutritional biochemistry established the menaquinone family in the latter 20th century. The compound gained significant scientific attention following the Rotterdam Study publication in 2004, which elevated long-chain menaquinones from a dietary curiosity to a subject of active cardiovascular and bone health research in Western medicine.

Health Benefits

- **Bone Mineralization Support**: MK-7 activates osteocalcin through gamma-carboxylation of its glutamate residues, enabling osteocalcin to bind hydroxyapatite and anchor calcium into bone matrix; RCT data in postmenopausal women show significant attenuation of age-related bone mineral density loss with 180 mcg/day over three years.
- **Vascular Calcification Inhibition**: MK-7 carboxylates matrix GLA protein (MGP), the most potent known inhibitor of vascular calcification; adequately carboxylated MGP sequesters calcium in the arterial wall, preventing pathological mineralization linked to cardiovascular risk.
- **Arterial Elasticity Improvement**: Clinical data indicate that MK-7 supplementation reduces circulating dp-ucMGP (dephosphorylated uncarboxylated MGP), a biomarker of vascular calcification activity, and has been associated with improved pulse wave velocity—a direct measure of arterial stiffness—in supplemented individuals.
- **Extended Carboxylation Efficiency**: The 48–92 hour plasma half-life of MK-7 sustains activation of extrahepatic vitamin K-dependent proteins between doses, unlike short-chain MK-4 or K1, ensuring continuous osteocalcin and MGP carboxylation in bone, vasculature, pancreas, and heart tissue.
- **Potential Metabolic Support**: Carboxylated osteocalcin functions as a hormone influencing insulin secretion and sensitivity; by maximizing osteocalcin carboxylation, MK-7 may contribute to improved glucose metabolism, though this pathway requires further dedicated clinical investigation.
- **Cardiovascular Protective Effects**: Population studies, including the Rotterdam cohort, associate higher dietary intake of long-chain menaquinones (MK-7 through MK-9) with significantly reduced coronary heart disease risk and aortic calcification scores, supporting a cardioprotective role distinct from vitamin K1.
- **Blood Coagulation Pathway Activation**: Like all vitamin K forms, MK-7 supports hepatic carboxylation of coagulation factors II, VII, IX, and X, though its primary clinical distinction lies in extrahepatic tissue activity where K1 and MK-4 demonstrate insufficient sustained effect.

How It Works

MK-7 functions as an obligate cofactor for the enzyme gamma-glutamyl carboxylase (GGCX), which converts specific glutamate (Glu) residues to gamma-carboxyglutamate (Gla) residues in vitamin K-dependent proteins; this carboxylation reaction requires the reduced hydroquinone form of MK-7, which is simultaneously oxidized to MK-7 epoxide and then regenerated by vitamin K epoxide reductase (VKOR). The two principal extrahepatic targets are osteocalcin, produced by osteoblasts—whose carboxylation is essential for calcium-binding affinity and bone matrix integration—and matrix GLA protein (MGP), expressed in vascular smooth muscle cells and chondrocytes, whose carboxylated form binds and sequesters free calcium ions to prevent ectopic mineralization. MK-7's polyisoprenoid side chain of seven isoprene units confers high lipophilicity and tight binding to plasma lipoproteins (primarily LDL and HDL), producing its markedly extended half-life of 48–92 hours versus approximately 1–2 hours for K1, which enables sustained tissue-level carboxylation activity between supplemental doses. Additionally, the lipophilic character of MK-7 facilitates distribution into peripheral tissues including liver, pancreas, heart, and arterial wall, and allows blood-brain barrier crossing, suggesting potential neuroactive roles that remain under investigation.

Scientific Research

The clinical evidence base for MK-7 is moderate in quality, comprising several well-designed randomized controlled trials (RCTs), mechanistic human studies, and supporting observational data, though large-scale multi-center trials remain limited. The most cited bone RCT (Knapen et al., 2013) enrolled 244 healthy postmenopausal women randomized to 180 mcg/day MK-7 or placebo for 3 years, demonstrating significant attenuation of age-related decline in bone mineral density at the lumbar spine and femoral neck, alongside reductions in uncarboxylated osteocalcin. For vascular outcomes, the VitaK-CAC trial investigated MK-7 supplementation (180 mcg/day) in subjects with coronary artery calcification and found no significant reduction in calcium score progression versus placebo, while other smaller trials (Westenfeld et al., 2012) demonstrated significant reductions in dp-ucMGP and improved pulse wave velocity in healthy adults after 8 weeks at 360 mcg/day. The Rotterdam Study, a large prospective cohort (n=4,807), provided influential observational evidence linking higher long-chain menaquinone intake to reduced cardiovascular mortality and aortic calcification, though this does not establish causality; overall, the evidence is strongest for bone biomarker endpoints and moderate for vascular calcification biomarkers, with large definitive RCTs on hard cardiovascular endpoints still needed.

Clinical Summary

Across RCTs, MK-7 supplementation at 180 mcg/day for 3 years significantly reduced the rate of bone mineral density loss at the lumbar spine (L1–L4) and femoral neck in postmenopausal women, with concurrent reductions in uncarboxylated osteocalcin (ucOC) indicating improved carboxylation status. Vascular trials demonstrate consistent dose-dependent reductions in dp-ucMGP—a validated biomarker of vascular calcification activity—at doses of 180–360 mcg/day within 8–12 weeks, and one trial reported a statistically significant improvement in carotid-femoral pulse wave velocity (a measure of arterial stiffness) after supplementation. The VitaK-CAC trial in subjects with established coronary artery calcification did not show significant reduction in CT-measured calcium scores, suggesting MK-7 may be more effective in preventing calcification progression than reversing established calcific lesions. Confidence in the bone mineralization and vascular biomarker endpoints is moderate-to-good (supported by biological plausibility and multiple trials), while confidence in hard cardiovascular event reduction remains preliminary, awaiting adequately powered outcome trials.

Nutritional Profile

Vitamin K2 MK-7 is a pure bioactive compound rather than a complex food matrix; as a fat-soluble quinone, it provides no macronutrient content and negligible caloric value at supplemental doses of 100–200 mcg. Its defining structural feature is a 2-methyl-1,4-naphthoquinone (menadione) ring system with a seven-unit all-trans polyisoprenoid side chain, conferring a molecular weight of approximately 649 g/mol and high lipid solubility (log P approximately 14). In its natural food source natto, MK-7 occurs at concentrations of approximately 900–1,000 mcg per 100 g wet weight, accompanied by other menaquinones (MK-4 through MK-13 in lesser amounts), protein, isoflavones, nattokinase, and pyrroloquinoline quinone (PQQ). Bioavailability is dependent on micellar solubilization in the gut requiring dietary fat, bile salt activity, and intact lymphatic transport via chylomicrons; conditions impairing fat absorption (cholestasis, pancreatic insufficiency, inflammatory bowel disease) significantly reduce MK-7 uptake.

Preparation & Dosage

- **Standard Supplement Capsule/Tablet (Natural Fermented MK-7)**: 100–200 mcg daily; the most widely used clinical dose is 180 mcg/day, shown effective in bone density trials.
- **High-Dose Vascular Protocol**: 360 mcg/day has been used in vascular calcification biomarker studies; doses above 200 mcg/day should be used with physician guidance, particularly in those on anticoagulant therapy.
- **Source Purity Standard**: Prefer natural fermentation-derived MK-7 with >99% all-trans isomer content; synthetic MK-7 may contain higher proportions of inactive cis-isomers that do not contribute to carboxylation activity.
- **Traditional Food Form (Natto)**: Approximately 40–50 mcg MK-7 per 10 g serving of natto; traditional Japanese consumption of 30–100 g natto daily can supply 120–500 mcg MK-7 from dietary sources alone.
- **Timing and Absorption**: MK-7 is fat-soluble and should be taken with the largest meal of the day containing dietary fat to maximize lymphatic absorption; peak plasma concentration occurs approximately 4 hours post-ingestion.
- **Bioavailability Optimization**: Co-ingestion with vitamin D3 and dietary calcium enhances the functional synergy for bone mineralization; absorption is significantly reduced in fat-restricted diets or malabsorptive conditions.
- **Standardization**: Quality supplements are standardized and quantified by HPLC at 248 nm, with certificates of analysis confirming trans-isomer percentage and absence of cis-contamination.

Synergy & Pairings

MK-7 demonstrates well-characterized synergy with vitamin D3 (cholecalciferol), as D3 upregulates osteocalcin gene expression while MK-7 provides the cofactor required to carboxylate and functionally activate the resulting osteocalcin protein—the combination is more effective for bone mineralization than either compound alone, and this pairing is supported by multiple clinical bone health trials. Dietary calcium co-administration completes the physiological triad for bone matrix formation, as carboxylated osteocalcin and MGP serve as the molecular scaffold and regulatory gates for calcium deposition, making the MK-7 + D3 + calcium combination the foundational bone health stack in evidence-based supplementation protocols. Magnesium additionally supports this stack by serving as a cofactor for vitamin D hydroxylation enzymes and contributing to bone crystal structure, while omega-3 fatty acids may enhance MK-7 absorption by improving micellar solubilization in the small intestine.

Safety & Interactions

Vitamin K2 MK-7 is well tolerated at supplemental doses of 100–360 mcg/day, with no documented adverse effects in published clinical trials at these levels; unlike the synthetic vitamin K precursor menadione (K3), purified MK-7 does not carry risks of hemolytic anemia or hepatotoxicity. The most clinically significant drug interaction is with vitamin K antagonist anticoagulants, particularly warfarin (coumadin) and acenocoumarol, which exert their anticoagulant effect by inhibiting VKOR—the same enzyme that regenerates the active form of MK-7; supplemental MK-7 can meaningfully antagonize warfarin's anticoagulant effect and elevate INR unpredictably, making it contraindicated without close medical supervision in patients on these medications. Patients on newer direct oral anticoagulants (DOACs such as apixaban, rivaroxaban, dabigatran) do not share this pharmacodynamic interaction, as DOACs act independently of the vitamin K cycle, though physician consultation is still advisable. Pregnancy and lactation safety data for supplemental MK-7 doses are limited; dietary intake from natto is considered safe, and vitamin K in general is required for neonatal coagulation, but high supplemental doses during pregnancy or lactation should be used only under medical guidance; no established tolerable upper intake level (UL) has been set by major regulatory bodies for MK-7 specifically.